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Abstract We have previously demonstrated that the E3
ligase Human Constitutive Photomorphogenic Protein
(huCOP1) is expressed in human keratinocytes and nega-
tively regulates p53. The MutS homolog 2 (MSH2) protein
plays a central role in DNA MMR mechanism and is
implicated in the cellular response to anticancer agents,
such as cisplatin. Our aim was to clarify whether huCOP1
plays a role in DNA MMR by affecting MSH2 protein
level in human keratinocytes. To define the role of huCOP1
in DNA mismatch repair, we determined whether huCOP1
affects MSH2 abundance. MSH2 protein level was detec-
ted by immunocytochemical staining using a keratinocyte
cell line in which the expression level of huCOP1 was
stably decreased (siCOP1). To investigate whether
huCOP1 silencing influences cisplatin-induced cell death,
control and siCOP1 keratinocyte cells were treated with
increasing concentrations of cisplatin and cell viability was
recorded after 48 and 96 h. Stable silencing of huCOP1 in
human keratinocytes resulted in a reduced level of MSH2
protein. huCOP1 silencing also sensitized keratinocytes to
the interstrand crosslinking inducer cisplatin. Our results
indicate that decreased huCOP1 correlates with lower
MSH2 levels. These protein level changes lead to increased
sensitivity toward cisplatin treatment, implicating that
huCOP1 plays a positive role in maintaining genome
integrity in human keratinocytes.
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Introduction
Constitutive Photomorphogenic Protein 1 (COP1) was first
identified as a central negative regulator of light-regulated
development in Arabidopsis thaliana [1]. The human
orthologue was identified in 2003 [2]. COP1 is a well-
conserved E3 ubiquitin ligase that regulates various cellu-
lar functions, such as proliferation and survival, through
ubiquitin-mediated protein degradation in mammals,
including humans [3, 4]. Several putative targets of mouse
and human COP1 (huCOP1) have been identified, includ-
ing COP1 itself, p53, JUN and ETS variant family mem-
bers. Transfection studies in cancer cell lines have
suggested that huCOP1 targets p53 for ubiquitylation and
proteasomal degradation [5].
We have previously demonstrated that huCOP1 is
expressed in human keratinocytes, regulates p53, and
potentially plays a pathogenic role in basal cell carcinoma
and/or in squamous cell carcinoma [6, 7]. These data
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collectively suggest that huCOP1 may have a role in DNA
damage repair, and deciphering its role in these processes
may bring us closer to understanding the DNA repair
mechanism in keratinocytes.
DNA mismatch repair (MMR) is an ancient and con-
served mechanism that significantly contributes to the
accurate preservation of genetic material. MMR mainte-
nance of genomic integrity is performed by correcting
replicative mismatches (nucleotide mispairs, insertion/
deletion loops) that escape DNA polymerase proofreading
[8]. The involvement of the mutS homolog 2 (MSH2)
protein in DNA MMR is well characterized. MMR activity
begins with mismatch recognition either by MutSa, a
heterodimer of MSH2 and MSH6 proteins, or by MutSb, a
heterodimer of MSH2 and MSH3 [9].
MutSa proteins are degraded by the ubiquitin–protea-
some pathway in a cell-type-dependent manner, indicating
that one or several regulator(s) may interfere with
huMutSa protein ubiquitination and degradation. Loss or
depletion of MutSa from cells leads to microsatellite
instability [10–13].
Several well-defined interactor molecules effecting
MSH2 stability and/or activity are known: protein kinase C
(PKC) is involved as a positive regulator of MMR activity,
and the atypical PKC zeta regulates ubiquitination, degra-
dation, and levels of huMutSa proteins. PKC zeta interacts
with huMSH2 and huMSH6 proteins and phosphorylates
both [14]. It has also been published that MSH2 interacts
with several class I and II histone deacetylases (HDAC).
HDAC6 deacetylates and ubiquitinates MSH2, leading to
MSH2 degradation and reduced cellular sensitivity to
DNA-damaging agents [15]. Namdar et al. [16] recently
demonstrated that selective inhibition of HDAC6 induces
DNA damage and sensitizes transformed cells to anticancer
agents. In contrast, other publications report on hypersen-
sitivity of MutSa protein-depleted cells to DNA interstrand
crosslink-inducing (ICL) agents [11–13].
An increasing body of evidence suggests the role of
huCOP1 in genome integrity, e.g., huCOP1-mediated p53
degradation was impaired in response to DNA damage,
allowing p53 stabilization and activation [5, 17–19]. Based
on our previous results with huCOP1 expression and
function in keratinocytes, we hypothesized that this mole-
cule is involved in the maintenance of genome integrity.
Therefore, we initiated a set of experiments to investigate
whether huCOP1 has a role in the regulation of MSH2
abundance in human keratinocytes.
In this paper, we describe that decreased huCOP1 level
is correlated with downregulated MSH2 levels in human
keratinocytes. Moreover, we provide data on increased
sensitivity of keratinocyte cells to cisplatin treatment that
results from decreased huCOP1 level.
Materials and methods
Cell culture
A HPV-immortalized human keratinocyte cell line (HPV-
KER clone II/15), in which TP53 is intact, was used for the
establishment of the siCOP1 cell line [20]. The ker-
atinocyte cell lines used in the experiments—control and
siCOP1, in which the expression level of huCOP1 was
stably decreased—have been described previously [7].
HPV-KER cells were maintained in keratinocyte serum-
free medium (Gibco Keratinocyte SFM Kit; Life Tech-
nologies, Copenhagen, Denmark) supplemented with 1%
antibiotic/antimycotic solution (PAA, Pasching, Austria)
and 1% L-glutamine (PAA) at 37 C in a humidified
atmosphere containing 5% CO2. The medium was changed
every 2 days.
Immunocytochemistry
Control and siCOP1 keratinocytes were grown on culture
slides (BD Falcon, Bedford, MA, USA) and immunos-
tained 48 h after seeding. Immunocytochemistry was car-
ried out using a previously described procedure [7]. As
primary antibody, the mouse monoclonal anti-human
MSH2 antibody was used at a dilution of 1:50 (product no.
IR08561, Clone FE11, Dako, Denmark). After rinsing with
TBS, cells were incubated with Alexa Fluor 647-labeled
anti-mouse secondary antibody produced in goat (Invitro-
gen, Carlsbad, CA, USA) at a dilution of 1:400 for 3 h in
the dark at room temperature. The subsequent semiquan-
titative analysis was carried out using the Metamorph
software (Universal Imaging Corp., Sunnyvale, CA, USA).
Real-time qRT-PCR experiments
Total RNA was isolated from control and siCOP1 cells
using the Direct-zolTM RNA MiniPrep (Zymo Research
Corporation, Irvine, CA, USA) according to the manufac-
turer’s instructions. cDNA was synthesized from 5 lg total
RNA with the Maxima First Strand cDNA Synthesis Kit
for RT-PCR (Thermo Scientific, Waban, MA, USA).
Real-time qRT-PCR experiments were carried out with
the Universal Probe Library system (F. Hoffmann-La
Roche AG, Basel, Switzerland). Sequences of the primers
used for PCR amplification:
MSH2:
FWD: CCAGCAGCAAAGAAGTGCTA; REV: GCA
AAATGAGGCACTGGTCT; UPL probe No: 21;
18S:
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FWD: CGCTCCACCAACTAAGAACG; REV: CTCA
ACACGGGAAACCTCAC; UPL probe No: 77.
Immunoprecipitation
Ubiquitinated proteins were immunoprecipitated from total
cell lysates (1.0 million cells) using the Immunoprecipita-
tion Kit Protein G (Roche Applied Science, Penzberg,
Germany) and anti-human ubiquitin mouse primary anti-
body in 50 ll final volume (cat. no. sc-52750, Santa Cruz
Biotechnology Inc., Heidelberg, Germany). Parallelly,
MSH2 antibody produced in mouse (Abcam, Cambridge,
UK) or HDAC6 antibody produced in rabbit (Santa Cruz
Biotechnology Inc., Heidelberg, Germany) were also used
for immunoprecipitation. Immunoprecipitated proteins
were size separated on a 10% SDS–polyacrylamide gel,
and western blots were performed using MSH2 or HDAC6
antibody at 1:500 or 1:200 dilution to detect these proteins
of the loaded samples. Alkaline phosphatase-conjugated
anti-mouse or anti-rabbit IgG (Sigma-Aldrich, St. Louis,
MO, USA) were used as secondary antibodies and the blots
were developed using 5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium as substrate.
Cell viability assay
Cell viability was assessed using the XTT assay (Roche,
Basel, Switzerland). This method is based on the fact that
metabolically active cells cleave the yellow tetrazolium
salt XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide) which then forms an orange
formazan dye. The amount of formazan dye directly cor-
relates with the number of metabolically active cells
[21, 22].
For treatment with cisplatin (1 mg/ml solution, Ebewe
Pharma, Vienna, Austria), cells were seeded in triplicate on
a 96-well plate at 7.5 9 103 cells per well in 150 ll media.
After 24 h of incubation in a humidified incubator at 37 C
and 5% CO2, media was removed and cells were treated
with the indicated doses of cisplatin (0.5–10 lM) in fresh
medium [23]. After 24 h of incubation, media containing
the cisplatin was removed, cells were washed twice with
PBS, and the cells were allowed to recover in 150 ll fresh
media for 2 or 4 days. Immediately before use, a XTT
labeling mastermix solution was prepared as recommended
by the manufacturer (Roche, Dublin, Ireland), and 150 ll
mastermix was pipetted into each well of the 96-well tissue
culture plate. Cells were incubated for a further 4 h. The
absorbance was then measured at 490 nm using a Victor2
1420 Multilabel Counter (Wallac, MA, USA). Results were
expressed as the percentage viability relative to the via-
bility of untreated cells.
Results
HuCOP1 is implicated in the regulation of MSH2
protein level in human keratinocytes
The important role of MSH2 in DNA MMR processes is
well known [9]. Our first goal was to reveal whether
huCOP1 affects MSH2 protein abundance in human ker-
atinocytes. For this purpose, we used a well-characterized
cell line in which the expression level of huCOP1 was
stably decreased (siCOP1) [7]. The MSH2 protein in
siCOP1 and control cells was visualized by immunocyto-
chemical staining. We detected a significant decrease
(80%) in the MSH2 protein level in the siCOP1 cells
compared to the control cells (Fig. 1a, b). Having detected
a difference in MSH2 protein expression by immunocyto-
chemistry, the question occurred if this was a consequence
of differential regulation at the RNA or protein level. To
clarify this issue, we carried out quantitative RT-PCR
analysis and measured the MSH2 mRNA levels in the
control and siCOP1 cell lines (Fig. 1c). We detected
approximately 1.8-fold higher level of MSH2 transcripts in
the siCOP1 line indicating that the decreased MSH2 pro-
tein abundance is not due to transcriptional downregulation
of the MSH2 gene in the siCOP1 cell line.
We also investigated huCOP1 regulation of MSH2
protein level in human keratinocytes. It is well established
that the ubiquitin–proteasome pathway is involved in the
regulation of MSH2 protein expression in the U937
(monocytic), HL-60 (myelocytic), HeLa (epithelial), and
MRC-5 (fibroblast) human cell lines [24]. Since huCOP1
functions as an E3 ubiquitin ligase, we compared the
ubiquitination of the MSH2 protein in the siCOP1 and
control cells. We immunoprecipitated the ubiquitinated
proteins from total protein extracts using an anti-ubiquitin
antibody, and then detected the amount of MSH2 protein in
the precipitate by western blot analysis. These experiments
revealed that ubiquitinated MSH2 protein was not
detectable in human keratinocytes. To confirm that the lack
of detection of the ubiquitinated MSH2 was not a result of
a technical failure, we included the HCD6 protein as a
positive control in the immunoprecipitation experiments
(Supplementary Fig. 1).
Silencing of huCOP1 sensitizes keratinocytes
to the interstrand crosslinking inducer cisplatin
MSH2 protein is a member of the DNA MMR pathway
contributing to the cellular response to DNA damage [9].
MSH2 is implicated in the cellular response to anticancer
agents, such as cisplatin, a DNA interstrand crosslink-in-
ducing (ICL) agent [10–13]. Based on the results of our
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Fig. 1 Determination of MSH2
mRNA and protein expression
in siCOP1 and control cells.
a MSH2 protein levels of




b subjected to semiquantitative
analysis. c Relative MSH2
transcript levels in siCOP1 cells
compared to the control cells
measured by real-time RT-PCR
analysis. Values reflect the gene
expression changes in siCOP1
cells compared to the control
cells. Expression levels were
normalized to the 18S ribosomal
RNA. The average of three
independent experiments is
shown. Black bars control cells;
gray bars siCOP1 cells
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protein analysis, we hypothesized that huCOP1 plays a role
in the maintenance of genome integrity. We investigated
whether huCOP1 silencing has an effect on cisplatin-in-
duced cell death. To this end, control and siCOP1 cells
were treated with increasing concentrations of cisplatin
(0.5–10 lM) and cell viability was recorded after 48
(Fig. 2a) and 96 h (Fig. 2b). We found that siCOP1 cells
displayed a significant hypersensitivity when exposed to
cisplatin: the reduced level of huCOP1 caused a sixfold
decrease in cell survival 48 h after treatment, and a 12-fold
decrease 96 h after treatment with 10 lM cisplatin. These
results suggest that huCOP1 influences the ICL repair
mechanism in keratinocytes by indirectly modulating the
MSH2 protein level in the cells.
Discussion
The ubiquitin–proteasome system (UPS) has emerged as a
key regulatory mechanism in DNA repair pathways and in
genome maintenance. Consequently, de-regulation of this
system may lead to the development of various cancers
[25]. The huCOP1 protein, an E3 ubiquitin ligase, pro-
motes ubiquitin-dependent protein degradation [26–29].
An increasing body of evidence points to the role of
huCOP1 in the maintenance of genome integrity
[17, 19, 30, 31]. It has been previously demonstrated that
huCOP1 is overexpressed in cancer cells and represses
p53-dependent tumor suppression via the UPS [5].
MSH2 is a protein involved in DNA MMR, which plays
an important role in the maintenance of genomic integrity
by correcting replicative mismatches (nucleotide mispairs,
insertion/deletion loops) that escape DNA polymerase
proofreading [9].
To investigate the role of huCOP1 in DNA repair of
human keratinocytes, we studied its effect on the
abundance of the MSH2 MMR protein in a well-charac-
terized siCOP1 human keratinocyte cell line. Our data
revealed that the level of MSH2 protein was decreased in
the siCOP1 cells. The slightly elevated MSH2 mRNA level
detected in these cells indicates also that huCOP1 is not
implicated in the transcriptional regulation, but it effects
the MSH2 protein abundance in human keratinocytes. The
ubiquitin–proteasome complex is responsible for the
degradation of MutSa proteins, and thus for the ubiquiti-
nation of MSH2 in Saccharomyces cerevisiae, U937, HL-
60, HeLa, and MRC-5 cell lines [24, 32]. Arlow and co-
workers proposed that monomeric MSH2 is targeted by
different ubiquitin ligases [32]. Since huCOP1 is a well-
known E3 ubiquitin ligase, the question arose whether
huCOP1 is able to influence MSH2 protein levels via the
ubiquitin–proteasome system. To investigate if the
decreased MSH2 level observed in siCOP1 cells is the
consequence of the increased ubiquitination rate of the
protein, we performed an immunoprecipitation assay using
siCOP1 and control cells. In our experiments, ubiquitinated
MSH2 protein was not detected in human keratinocytes.
Similarly, Hernandez-Pigeon et al. [24] have described that
they were not able to detect ubiquitinated MSH2 in
epithelial cells and fibroblasts.
The fact that we could not detect ubiquitinated MSH2
protein in control and siCOP1 human keratinocytes indi-
cates that huCOP1 does not modulate MSH2 protein levels
directly by ubiquitination. It is well known that MSH2 can
form heterodimers with MSH3 and MSH6 and that main-
taining a constant ratio of the monomers is advantageous
for cells [24]. It has been proven by genetic and bio-
chemical approaches that the stoichiometry of MMR pro-
teins is important. The possibility that MSH3 and/or MSH6
are ubiquitinated and the heterodimers subsequently
undergo proteasomal degradation might explain the
decreased level in keratinocytes of MSH2 that is not
Fig. 2 Sensitivity of siCOP1 and control cells to cisplatin. a Average
survival of siCOP1 and control cells after 2 days and b after 4 days of
treatment with 0.5–10 lM cisplatin. Cell survival was determined by
an XTT assay performed in triplicate. The bars represent the standard
error of the means. Statistically significant differences between
untreated and treated cells are indicated with asterisk (p\ 0.05,
Student’s two-tailed t test). Black line control cells; gray line siCOP1
cells
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ubiqutinated. The function of the unidentified E3 ubiquitin
ligase(s) and/or protease(s) acting in this process is likely
partly inhibited by huCOP1. Similarly, the target of
huCOP1 in these processes might be one of the E3 ligases
that ubiquitinates MSH2 interacting partners, such as
HDAC6 or PKC zeta.
MSH2 is implicated in the cellular response to DNA
damage [9]. Many anticancer agents, such as cisplatin,
induce DNA damage, primarily at guanine residues. This
damage generates monoadducts, intrastrand or interstrand
crosslinks in DNA, leading to the inhibition of DNA
replication and transcription and ultimately to cell death
[33, 34]. Previous reports have suggested that MMR-de-
fective cells are hypersensitive to ICLs [12, 13]. Although
other reports, especially those dealing with the role of
HDAC6 activity on MSH2 level, contradict this scenario
[15, 16], the detailed mechanisms behind those phenomena
are not known. It has been shown that the MSH2 level
correlates with the activity of repair mechanisms in the
cells. As we detected decreased MSH2 levels in siCOP1
keratinocytes, we investigated whether reduced huCOP1
abundance influences cisplatin-induced cell death. We
found that siCOP1 cells displayed hypersensitivity when
exposed to cisplatin, supporting a potential role of huCOP1
in the ICL repair mechanism.
Taken together, our results show that decreased huCOP1
levels correlate with lower MSH2 levels in keratinocytes.
These protein level changes lead to increased sensitivity
toward cisplatin treatment, implying that huCOP1 plays a
positive role in maintaining genome integrity.
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